Delta Financial Group Inc. Purchases Shares of 4,047 Gilead Sciences, Inc. (NASDAQ:GILD)

Delta Financial Group Inc. acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,047 shares of the biopharmaceutical company’s stock, valued at approximately $374,000.

Several other large investors also recently made changes to their positions in the business. Atlantic Family Wealth LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $370,000. Pavion Blue Capital LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $217,000. Howard Capital Management Inc. grew its stake in shares of Gilead Sciences by 12.2% in the fourth quarter. Howard Capital Management Inc. now owns 41,922 shares of the biopharmaceutical company’s stock valued at $3,872,000 after buying an additional 4,574 shares in the last quarter. Wealthspire Advisors LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $248,000. Finally, TCW Group Inc. lifted its position in Gilead Sciences by 1.1% during the 4th quarter. TCW Group Inc. now owns 30,277 shares of the biopharmaceutical company’s stock worth $2,797,000 after acquiring an additional 343 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.1 %

GILD opened at $109.95 on Monday. The stock’s fifty day moving average is $95.41 and its 200-day moving average is $88.83. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $111.03. The company has a market capitalization of $137.03 billion, a PE ratio of 297.16, a P/E/G ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio is currently 832.43%.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 713,000 shares of company stock worth $67,945,181. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Citigroup assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective for the company. BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.